Výsledky vyhledávání - "Sandra Zhang"

Report

Training-Free Sketch-Guided Diffusion with Latent Optimization

Autor: Ding, Sandra Zhang, Mao, Jiafeng, Aizawa, Kiyoharu

Based on recent advanced diffusion models, Text-to-image (T2I) generation models have demonstrated their capabilities in generating diverse and high-quality images. However, leveraging their potential for real-world content creation, particularly in

Externí odkaz: http://arxiv.org/abs/2409.00313

Zobrazit plný text záznamu

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

Autor: Ulhas P. Naik, Srikanth Nagalla, Matt S. Anderson, Jocelyn Gilmartin, Brittany Walker, Walter K. Kraft, Sandra Zhang, Ferdous Gheyas, Derek L Chappell, Jay Horrow, Rebecca E Wrishko

Publikováno v: Clinical and Translational Science

The effect of the protease-activated receptor-1 (PAR-1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two-period, open-label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::febe83de9c9e70419b893c737563ea23
https://doi.org/10.1111/cts.12405

Zobrazit plný text záznamu

Plný text ve formátu HTML

Abstract 527: Vorapaxar Does Not Increase Bleeding Time

Autor: Matt S. Anderson, Rebecca E Wrishko, Jocelyn Gilmartin, Srikanth Nagalla, Walter K. Kraft, Derek L Chappell, Sandra Zhang, Uhlas P Naik

Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 36

Vorapaxar is a novel PAR-1 inhibitor approved in the US and EU to reduce risk of thrombotic CV events in patients with a history of MI, and in the US also in patients with PAD. It does not affect coagulation tests (TT, PT, aPTT, ACT, ECT). Aspirin an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6da4a9fa20c72ce009b59c41d8a8362
https://doi.org/10.1161/atvb.36.suppl_1.527

Zobrazit plný text záznamu

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration

Autor: Deanne Jackson Rudd, Sabrina Fox-Bosetti, Aubrey Stoch, Vanessa Levine, Kerry L. Fillgrove, Marian Iwamoto, Randolph P. Matthews, Charles Tomek, Sandra Zhang

Publikováno v: Open Forum Infectious Diseases

Background MK-8591 is a novel, highly potent, nucleoside reverse transcriptase translocation inhibitor (NRTTI) that is in development for the treatment of HIV-1 infection. MK-8591 is not expected to be a perpetrator or victim of drug–drug interacti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e57a090d4ead426b8ff7df543f364d6d
http://europepmc.org/articles/PMC6255630

Zobrazit plný text záznamu

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel

Autor: Darin Brimhall, Kerry L. Fillgrove, Marian Iwamoto, Randolph P. Matthews, Sandra Zhang, Deanne Jackson Rudd, Aubrey Stoch, Wendy Ankrom, Kezia Gravesande, Daniel Jonathan

Publikováno v: Open Forum Infectious Diseases

Background Over 2 million girls and young women are living with HIV, being newly infected at disproportionately high rates. HIV infection adds risks to pregnancy, including vertical transmission and maternal death. Hormonal contraceptives are among t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8854b8c72d13c5b8afd63ceedad622c
https://doi.org/10.1093/ofid/ofy210.559

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání